Drug Delivery to the Brain

Anatomy and physiology of the blood-brain barriers.- Recent Progress in Blood-Brain Barrier and Blood-CSF Barrier Transport Research: Pharmaceutical Relevance for Drug Delivery to the Brain.- Blood-Brain Barrier (BBB) Pharmacoproteomics: A New Research Field Opened up by Quantitative Targeted Absolute Proteomics (QTAP).- Drug Metabolism at the Blood-Brain and Blood-CSF Barriers.- Pharmacokinetic Concepts in Brain Drug Delivery.- In vitro models of blood-brain barriers.- In situ and in vivo animal models.- Principles of PET and its Role in Understanding Drug Delivery to the Brain.- PKPD Aspects of Brain Drug Delivery in a Translational Perspective.- Drug Discovery Methods for Studying Brain Drug Delivery and Distribution.- Prediction of Drug Exposure in the Brain from the Chemical Structure.- Integrated Approach to Optimizing CNS Penetration in Drug Discovery: From the old to the new Paradigm and Assessment of Drug-Transporter Interactions.- Pharmacoeconomic Considerations in CNS Drug Development.- Intranasal Drug Delivery to the Brain.- Blood-To-Brain Drug Delivery using Nanocarriers.- Development of new Protein Vectors for the Physiologic Delivery of Large Therapeutic Compounds to the CNS- CNS Gene Therapy Utilizing Intravenously Administered Viral Vectors.- Neurosurgical Approaches: Drug Infusion Directly into the Parenchyma or Cerebrospinal Fluid.- Osmotic Opening of the BBB for Drug Treatment of Brain Tumors (Focus on Methodological Issues).- Emerging Engineering Technologies for Opening the BBB.- Disease Influence on BBB Transport in Inflammatory Disorders.- Disease Influence on BBB Transport in Neurodegenerative Disorders.- Drug Delivery in the Context of Stroke and Brain Trauma.- Which Drug or Drug Delivery Method can change Clinical Practice for Brain Tumor Therapy?.

Margareta Hammarlund-Udenaes (PhD) is a Professor in Pharmacokinetics and Pharmacodynamics (PKPD) at Uppsala University and the Head of the Translational PKPD Group. Her research is focused at studying pharmacokinetic aspects of BBB transport of drugs in relation to CNS effects, which has led to the development of new concepts and methods within the BBB transport area, focusing on unbound drug relationships. Dr. Hammarlund-Udenaes is an Associate Editor of Pharmaceutical Research and a member of the Editorial Advisory Board of Journal of Pharmaceutical Sciences and Fluids and Barriers of the CNS. She became an American Association of Pharmaceutical Scientists' Fellow in 2005. She is a frequent lecturer at conferences and in drug industry. Her company gives courses and advice in PKPD and BBB transport issues. She co-founded and has co-chaired several of the International Symposia on Microdialysis, and she is the Chair of the 'Barriers of the CNS' Gordon Conference in 2014.

Elizabeth C.M. de Lange (PhD) is Head of the Target Site Equilibration Group at the Division of Pharmacology of the Leiden Academic Center for Drug Research (LACDR). Her research program focuses on the development of generally applicable predictive PKPD models on CNS drugs using advanced in vivo animal models and mathematical modeling techniques, with a number of recent successes. She is an Editorial Board member of the journal Fluids and Barriers of the CNS, and an Editorial Advisory Board member of the Journal of Pharmaceutical Sciences and of Pharmaceutical Research. She has been the cofounder and (co-)Chair at the 1st, 2nd and 5th International Symposia on Microdialysis, and has been the Chair of the 9th International Conference on Cerebral Vascular Biology (2011). Among many other functions within the American Association of Pharmaceutical Scientists, she is the 2014 Chair of the Annual MeetingProgramming Committee. With her company "In Focus" (www.infocus-ecmdelange.nl)